Loading clinical trials...
Loading clinical trials...
Red Cell Lysis Buffer Application Versus Conventional Sample Processing in Endoscopic Ultrasonography (EUS)-Guided Biopsy for Solid Pancreatic Lesions
The goal of this clinical trial is to evaluate the application of red cell lysis buffer (RCLB) versus conventional sample processing in endoscopic ultrasonography (EUS)-guided biopsy for solid pancreatic lesions. The main questions it aims to answer are: whether the application of red cell lysis buffer improves histological tissue quality by decreasing blood contamination. Participants with solid pancreatic lesions who needs histological diagnosis will receive EUS-guided biopsy. The obtained specimens will be processed by RCLB and conventional formalin solution. Researchers will compare the blood contamination score of specimens in RCLB group with the conventional group see if the blood contamination can be improved.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Changhai Hospital
Shanghai, Shanghai Municipality, China
Start Date
September 15, 2023
Primary Completion Date
October 30, 2023
Completion Date
December 31, 2023
Last Updated
September 7, 2023
66
ESTIMATED participants
Red cell lysis buffer (RCLB) application
PROCEDURE
Conventional processing
PROCEDURE
Lead Sponsor
Changhai Hospital
NCT07017283
NCT07024199
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions